LUNG
Pulmonx Corp.
NASDAQ · Healthcare · Medical - Devices · US
$2.84
+4.23%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.77
From 52W high−10.43%
Volume762931.00
Market cap$123.47M
P/E (TTM)—
P/S (TTM)1.4x
Div yield—
Key dataNov 4, 2026
Open
$2.77
From 52W high
−10.43%
Volume
762931.00
Market cap
$123.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.4x
P/E (TTM)
—
RSI (14)
68.0
MomentumView details →
1D Return
+4.23%
YTD Return
+34.16%
SummaryUpdated Sep 1, 2026
Pulmonx Corporation (NASDAQ:LUNG) is a medical technology company founded in 1995 and headquartered in Redwood City, California. The company specializes in developing and commercializing minimally invasive devices for treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Since going public in October 2020, Pulmonx has focused on expanding its flagship Zephyr Endobronchial Valve system globally while developing complementary technologies to address the broader COPD patient population.
Similar companies
Latest newsMore news →